Bristol Myers Squibb (BMY) Land & Improvements (2025 - 2026)
Bristol Myers Squibb (BMY) reported Land & Improvements of $157.0 million for Q1 2026, little changed on a QoQ basis from $157.0 million in Q4 2025.
Bristol Myers Squibb (BMY) has 2 years of Land & Improvements data on file, last reported at $157.0 million in Q1 2026.
- Quarterly Land & Improvements changed N/A year-over-year to $157.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $157.0 million (changed N/A YoY) and the FY2025 annual result came in at $157.0 million, changed N/A from the prior year.
- Land & Improvements steadied at $157.0 million in Q1 2026 per BMY's latest filing, from $157.0 million in the prior quarter.
- Across five years, Land & Improvements topped out at $157.0 million in Q4 2025 and bottomed at $157.0 million in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Land & Improvements (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | - |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | - |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | - |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | - |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 157.00 Mn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 157.00 Mn |
| Dec 31, 2025 | 157.00 Mn |